Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

Saved in:
Bibliographic Details
Published in:European journal of haematology Vol. 110; no. 2; pp. 222 - 223
Main Authors: Regidor, Bernard Sean, Siddiqi, Dilawer, Beatty, Bethany Marie, Goldwater, Marissa‐Skye, Jew, Scott, Bujarski, Sean, Swift, Regina, Kim, Susanna, Berenson, James R.
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-02-2023
Subjects:
ADP-ribosyl Cyclase 1
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
anti‐CD38
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
CD38 antigen
daratumumab
Humans
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
venetoclax
anti-CD38
multiple myeloma
daratumumab
venetoclax
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13896